BioSpace News Archive

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”).

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day.

Piezo Motion, a Brain Scientific company, and Applied Mechatronics announce a partnership.

Replimune Group Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced financial results for the fiscal third quarter ended December 31, 2021 and provided a business update.

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time.

Dyve Biosciences, Inc. today announced a joint, two-year research collaboration with Moffitt Cancer Center.

The Lundquist Institute’s investigator Lina R. Nih, PhD, and her colleagues at Penn State have received a five-year, $2.29 million grant from the National Institute of Neurological Disorders and Stroke to explore the use of injectable porous biomaterials to target post-stroke immune response and promote new blood vessel and axon formation, processes known as angiogenesis and axonogenesis, respectively, at the site of the stroke.

The Hadassah Cancer Research Institute at the Hadassah University Medical Center in Jerusalem, announced that using artificial intelligence, researchers have developed, an algorithm to identify, with an unprecedented 96.5% level of accuracy, all possible deleterious mutations of TP53 gene which are commonly found in 50% of tumors.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific Nicolet RaptIR FTIR Microscope.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a wind energy contract with Repsol to address the entirety of the Company’s European power requirements with renewable energy by 2023.